Precision oncology company developing targeted therapies for patients with cancer driven by specific genetic alterations.
Tyra Biosciences is a precision oncology company focused on developing targeted therapies for patients with cancers driven by specific genetic alterations, particularly FGFR (fibroblast growth factor receptor) mutations and fusions. The company uses structure-based drug design and computational chemistry to create selective kinase inhibitors. Tyra's lead programs target cancers with FGFR alterations that have developed resistance to existing treatments. The company went public in 2021 and continues to advance its pipeline of precision oncology therapeutics through clinical development.
Tyra Biosciences has received investment from 1 venture capital firm.
Precision oncology company developing targeted therapies for patients with cancer driven by specific genetic alterations.
Tyra Biosciences has received investment from Canaan Partners. These venture capital firms and investors provide both capital and strategic support.
Tyra Biosciences has raised $200M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Tyra Biosciences was founded in 2018 and is headquartered in Carlsbad, California.
Tyra Biosciences operates in the Biotech sector. Precision oncology company developing targeted therapies for patients with cancer driven by specific genetic alterations.
